EU Committee Recommends Approval of Pfizer and Genmab's Tivdak for Cervical Cancer
Key Insights
The European Medicines Agency's CHMP has recommended marketing authorization for Tivdak, an antibody-drug conjugate developed by Pfizer and Genmab.
Tivdak is intended for the treatment of recurrent or metastatic cervical cancer (search) in adult patients.
Tivdak has already been approved in the United States for the same indication, recurrent or metastatic cervical cancer (search).
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for Tivdak (tisotumab vedotin), a cervical cancer (search) treatment developed by Pfizer in collaboration with Genmab. This decision marks a significant step towards expanding treatment options for patients with recurrent or metastatic cervical cancer within the European Union.
Tivdak, an antibody-drug conjugate (ADC), has already received approval in the United States for the treatment of recurrent or metastatic cervical cancer (search). The CHMP's positive opinion suggests that Tivdak may soon be available to patients in Europe facing this challenging disease.
The recommendation is based on clinical data demonstrating Tivdak's efficacy and safety in patients with recurrent or metastatic cervical cancer (search) who have progressed on or after prior systemic therapy. The precise details of the clinical trials and data leading to this recommendation were not available in the provided source material.
Cervical cancer (search) remains a significant health concern worldwide, with a substantial number of cases diagnosed annually. While advancements in screening and prevention have reduced incidence rates in some regions, there remains a critical need for effective treatments for patients with advanced-stage disease. The current treatment landscape for recurrent or metastatic cervical cancer often involves chemotherapy, radiation, and targeted therapies. The addition of Tivdak offers a new therapeutic option with a novel mechanism of action.
Tisotumab vedotin, the active ingredient in Tivdak, consists of a human monoclonal antibody directed against tissue factor (search) (TF), conjugated to the microtubule-disrupting agent vedotin. Upon binding to TF-expressing cancer cells, Tivdak is internalized, releasing vedotin and inducing cell cycle arrest and apoptosis.
The positive CHMP opinion will now be reviewed by the European Commission, which has the authority to grant marketing authorization for medicines in the European Union. If approved, Tivdak will provide a valuable new treatment option for patients with recurrent or metastatic cervical cancer (search).